Polymeric nanomaterials containing amino acids for controlled release of triacetyluridine

Official URL: https://dx.doi.org/10.1002/slct.202507057

Triacetyluridine (TAU) has higher oral bioavailability and represents a novel mechanism for delivering exogenous pyrimidines to the brain. It is commonly employed to mitigate the adverse effects of chemotherapy, attenuate toxicity, enhance the effectiveness of anticancer treatment, boost cognitive functions and memory, and provide therapeutic support for neurological and hereditary disorders. p(HEMA-MAC) was synthesized using non-surfactant emulsion polymerization. Then, they were modified for TAU specificity by using immobilized metal ion (Cu+’) affinity and characterized. Optimization of TAU adsorption conditions and controlled release studies of TAU were performed. At physiological Ph = 7.4, approximately 45.8% of 2 mg/mL TAU-loaded nanopolymers were shown to be controlled, efficient release within 90 min.